Allergan acquires neurotoxin start-up Bonti for $195mm

Sep 2018

Allergan PLC agreed to buy private biotech Bonti Inc., which is developing botulinum neurotoxin serotype E (BoNT/E)-derived candidates.

Acquisition
- Acquisition of Private Biotech
- Includes Earnout
- Payment Includes Cash
- Full Acquisition

Already a Strategic Transactions subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com

Related Companies

Allergan acquires neurotoxin start-up Bonti for $195mm

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice